JP Morgan Reinstates Underweight on Emergent BioSolutions
JP Morgan analyst Jessica Fye reinstates Emergent BioSolutions (NYSE:EBS) with a Underweight.
Read original at benzingaStocks · News reference
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:51 PM
- Checked
- Aug 5, 2026, 8:51 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
HC Wainwright & Co. Maintains Buy on Emergent BioSolutions, Lowers Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Emergent BioSolutions (NYSE:EBS) with a Buy and lowers the price target from $12 to $10.
Read original at benzingaU.S. CDC Says As Of August 6, 2,465 Confirmed Measles Cases Were Reported In U.S. In 2026; There Have Been 38 New Measles Outbreaks Reported In 2026, And 94% Of Confirmed Cases Are Outbreak-Associated
https://www.cdc.gov/measles/data-research/index.html
Read original at benzingaEmergent BioSolutions shares are trading lower after the company lowered its FY2026 sales guidance.
Read original at benzinga